Related Experiment Video

Updated: May 26, 2026

The Examination of Peroxidase-Positive Leukocytes in Semen
04:36

The Examination of Peroxidase-Positive Leukocytes in Semen

Published on: January 19, 2024

Myeloperoxidase in chronic kidney disease

A Madhusudhana Rao1, Usha Anand, C V Anand

  • 1Department of Biochemistry, PSG Institute of Medical Sciences and Research, Coimbatore, 641004 Tamil Nadu India.

Indian Journal of Clinical Biochemistry : IJCB
|January 3, 2012
PubMed

Insights

Plasma myeloperoxidase (MPO) levels decrease in chronic kidney disease (CKD) patients as kidney failure advances. This decline in MPO may be caused by the inhibitory effects of uremic toxins on the enzyme.

Area of Science:

  • Biochemistry
  • Nephrology
  • Cardiology

Background:

  • Myeloperoxidase (MPO) plays a role in cardiovascular disease (CVD) pathogenesis.
  • Patients with chronic kidney disease (CKD) face a heightened risk of developing CVD.
  • MPO, a pro-oxidant enzyme, may contribute to the increased CVD susceptibility in CKD patients.

Purpose of the Study:

  • To investigate plasma MPO levels in individuals with varying stages of CKD compared to healthy controls.
  • To explore the relationship between MPO levels and indicators of kidney function (GFR, urea, creatinine) in CKD patients.

Main Methods:

  • Plasma MPO levels were measured using a spectrophotometric assay.
  • Serum urea and creatinine were quantified using a clinical chemistry analyzer.
  • CKD patients were stratified into stages II-V (end-stage renal disease).

Main Results:

  • Mean plasma MPO levels were significantly lower in advanced stages of renal failure (P < 0.001).
  • A positive correlation was found between MPO and glomerular filtration rate (GFR) (r = +0.89, P < 0.001).
  • Negative correlations were observed between MPO and urea (r = -0.85, P < 0.001) and creatinine (r = -0.82, P < 0.001).
  • An inverse association between plasma MPO and urea was noted in CKD patients, but not in controls (P = 0.43).

Conclusions:

  • Plasma MPO levels decline with advancing renal failure in CKD patients.
  • Uremic toxins may exert an inhibitory effect on MPO activity, leading to lower plasma levels.
  • The findings suggest a complex interplay between MPO, kidney function, and uremic environment in CVD risk.
Keywords:
Cardiovascular diseaseChronic kidney diseaseMPO-hydrogen peroxide–chloride systemOxidative stressUraemic toxins

More Related Videos

Assessment of Vascular Function in Patients With Chronic Kidney Disease08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...